IMNM

Immunome Inc.

Pharmaceutical Preparations · SIC 2834CIK 1472012Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$7.0M

Net Income FY2025

$(212.0M)

EPS (Basic, as reported)

$-2.43

Net Margin FY2025

-3060.0%

ROE FY2025

-33.5%

Total Equity

$634.0M

Shares Out

114M

Business description

Immunome Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 14 → 7 -29.3% CAGR

Fiscal yearFY2019FY2020⚑FY2021FY2022⚑FY2023⚑FY2024⚑FY2025

Revenue————1497

Research & development(9)(7)(14)(23)(23)(130)(177)

General & administrative(2)(5)(11)(14)(20)(33)(44)

Total operating expenses(10)(12)(25)(37)(124)(315)(231)

Operating income(10)(12)(25)(37)(110)(306)(224)

Interest expense00—————

Interest & investment income00—————

Other income (expense), net—(6)00———

Income tax expense0000000

Net income(10)(18)(25)(37)(107)(293)(212)

EPS — basic—($5.26)($2.14)($3.09)($5.38)($5.00)($2.43)

EPS — diluted—($5.26)($2.14)($3.09)($5.38)($5.00)($2.43)

Shares outstanding — basic (M)—31212205987

Shares outstanding — diluted (M)—31212205987

⚑ Weighted-average shares changed ×4.00 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.67 between FY2022 and FY2023 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×2.95 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.47 between FY2024 and FY2025 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.